RPHM (Reneo Pharmaceuticals) Short-Term Capital Lease Obligation : $0.33 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Short-Term Capital Lease Obligation?

Reneo Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.33 Mil.

Reneo Pharmaceuticals's quarterly Short-Term Capital Lease Obligation stayed the same from Dec. 2023 ($0.33 Mil) to Mar. 2024 ($0.33 Mil) and stayed the same from Mar. 2024 ($0.33 Mil) to Jun. 2024 ($0.33 Mil).

Reneo Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.40 Mil) but then declined from Dec. 2022 ($0.40 Mil) to Dec. 2023 ($0.33 Mil).

Reneo Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Reneo Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals Short-Term Capital Lease Obligation Chart

Reneo Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.40

0.33

Reneo Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial														0.32	0.33	0.33	0.33	0.33

Reneo Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Reneo Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Reneo Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612

Website

https://www.reneopharma.com

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Executives

Ashley Hall	officer: Chief Development Officer	C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse	officer: Senior VP, Corporate Operation	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam	officer: VP of Finance & Administration	C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher	director	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal	officer: Chief Financial Officer	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher	director, officer: President and CEO	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson	officer: Chief Development Officer	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p.	10 percent owner	7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106